Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Anti-PD-1/CTLA-4 Antibody”

60 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 60 results

Testing effectiveness (Phase 2)UnknownNCT05522894
What this trial is testing

AK104 Alone or in Combination With Chemotherapy in the First-line Treatment of ESCC

Who this might be right for
Unresectable Esophageal Squamous Cell CarcinomaLocally Advanced Esophageal Squamous Cell CarcinomaMetastatic Esophageal Squamous Cell Carcinoma
Chinese Academy of Medical Sciences 80
Early research (Phase 1)Looking for participantsNCT04248569
What this trial is testing

DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Fibrolamellar Hepatocellular Carcinoma

Who this might be right for
Fibrolamellar Hepatocellular Carcinoma (FLC)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 56
Testing effectiveness (Phase 2)Study completedNCT03459222
What this trial is testing

An Investigational Study of Immunotherapy Combinations in Participants With Solid Cancers That Are Advanced or Have Spread

Who this might be right for
Advanced Cancer
Bristol-Myers Squibb 229
Testing effectiveness (Phase 2)Study completedNCT04868708
What this trial is testing

AK104（ an Anti-PD-1 and Anti-CTLA-4 Bispecific Antibody) in Recurrent or Metastatic Cervical Cancer

Who this might be right for
Recurrent or Metastatic Cervical Cancer
Akeso 50
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07533305
What this trial is testing

Efficacy and Safety of QL1706 Combined With Nab-paclitaxel and Cisplatin as 1st Line Therapy for Advanced or Metastatic Esophageal Squamous Cell Carcinoma

Who this might be right for
QL1706ESCCFirst-line Therapy
The First Affiliated Hospital of Henan University of Science and Technology 50
Testing effectiveness (Phase 2)Study completedNCT02694822
What this trial is testing

AGEN1884, an Anti-CTLA-4 Human Monoclonal Antibody in Participants With Advanced or Refractory Cancer and Who Have Progressed With PD-1/PD-L1 Inhibitor as Their Most Recent Therapy

Who this might be right for
Advanced Solid CancersAdvanced Solid Cancers Refractory to PD-1 and PD-L1 Therapies
Agenus Inc. 89
Early research (Phase 1)Study completedNCT03523819
What this trial is testing

CS1002 in Subjects with Advanced Solid Tumors

Who this might be right for
Solid Tumor, Adult
CStone Pharmaceuticals 91
Early research (Phase 1)Not Yet RecruitingNCT07619001
What this trial is testing

Evaluate the PK Similarity of AK104 in Healthy Chinese Male Participations

Who this might be right for
Healthy Male Adults Participants
Akeso 158
Testing effectiveness (Phase 2)Looking for participantsNCT06482801
What this trial is testing

Checkpoint Inhibitor Combinations Therapy as First Line for HCC Via IT

Who this might be right for
Liver CancerAntibody
Second Affiliated Hospital of Guangzhou Medical University 90
Early research (Phase 1)Looking for participantsNCT05142189
What this trial is testing

Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer

Who this might be right for
Non-Small Cell Lung Cancer
BioNTech SE 320
Testing effectiveness (Phase 2)Active Not RecruitingNCT04556253
What this trial is testing

AK104 in Locally Advanced MSI-H/dMMR Gastric Carcinoma and Colorectal Cancer

Who this might be right for
MSI-H/dMMR Gastric Carcinoma and Colorectal Cancer
Peking University 47
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06751277
What this trial is testing

QL1706 Combined with Chemotherapy in the Treatment of Recurrent or Metastatic Endometrial Cancer

Who this might be right for
Recurrent or Metastatic Endometrial Cancer
xiang yang 26
Testing effectiveness (Phase 2)Study completedNCT03222076
What this trial is testing

Nivolumab With or Without Ipilimumab in Treating Patients With Resectable Liver Cancer

Who this might be right for
Hepatocellular CarcinomaResectable Hepatocellular Carcinoma
M.D. Anderson Cancer Center 30
Early research (Phase 1)UnknownNCT03527251
What this trial is testing

Anti-CTLA-4 Antibody Followed by Anti-PD-1 Antibody in Recurrent or Metastatic NSCLC

Who this might be right for
Non Small Cell Lung Cancer
Sun Yat-sen University 10
Testing effectiveness (Phase 2)Active Not RecruitingNCT04043195
What this trial is testing

Nivolumab and Ipilimumab in Combination With Immunogenic Chemotherapy for Patients With Advanced NSCLC

Who this might be right for
Advanced NSCLC
Hatim Husain 30
Testing effectiveness (Phase 2)Looking for participantsNCT07447570
What this trial is testing

Iparomlimab and Tuvonralimab Plus Hypofractionated Radiotherapy and Chemotherapy for HAHNSCC

Who this might be right for
Head and Neck CancerRadiotherapyAnti-PD-1/CTLA-4 Antibody
Second Affiliated Hospital, Zhejiang University, School of Medicine 27
Testing effectiveness (Phase 2)Active Not RecruitingNCT05824481
What this trial is testing

Study of Cadonilimab (AK104) Plus Lenvatinib in Patients With Advanced Endometrial Cancer

Who this might be right for
Endometrial CancerEndometrial Adenocarcinoma
Sun Yat-sen University 32
Testing effectiveness (Phase 2)Ended earlyNCT03430063
What this trial is testing

REGN2810 and Ipilimumab in Patients With Lung Cancer

Who this might be right for
Advanced Non-Small Cell Lung Carcinoma
Regeneron Pharmaceuticals 28
Testing effectiveness (Phase 2)Study completedNCT04728321
What this trial is testing

Anti-PD-1/CTLA-4 Bispecific AK104 Alone or in Combination With Lenvatinib in Advanced Hepatocellular Carcinoma

Who this might be right for
Hepatocellular Carcinoma
Akeso 32
Testing effectiveness (Phase 2)Study completedNCT04444167
What this trial is testing

Anti-PD-1/CTLA-4 Bispecific AK104 Plus Lenvatinib in First-line Advanced Hepatocellular Carcinoma

Who this might be right for
Hepatocellular Carcinoma
Akeso 59
Next Page